| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/29/2004 | WO2004037173A3 Method for treating erectile dysfunction and increasing libido in men |
| 07/29/2004 | WO2004035536A3 Azo compounds for type i phototherapy |
| 07/29/2004 | WO2004032866A3 Therapeutic formulations |
| 07/29/2004 | WO2004024889A3 Production of bispecific molecules using polyethylene glycol linkers |
| 07/29/2004 | WO2004010972A3 Pellicle-resistant gelatin capsule |
| 07/29/2004 | WO2004004663A3 Compositions and methods for ligament growth and repair |
| 07/29/2004 | WO2003092621A3 Composition and method for dermatological treatment |
| 07/29/2004 | WO2003090640A3 Microbial cellulose wound dressing for treating chronic wounds |
| 07/29/2004 | WO2003075741A3 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 07/29/2004 | WO2003070881A3 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/29/2004 | WO2003044076A8 Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them |
| 07/29/2004 | WO2003028634A8 Method of treatment using ligand-immunogen conjugates |
| 07/29/2004 | US20040148003 Drug-polymer coated stent with pegylated styrenic block copolymers |
| 07/29/2004 | US20040147737 cellulose ether esters of lactic acid and of hydroxyacetic acid; slow-release pharmaceutical preparations |
| 07/29/2004 | US20040147673 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 07/29/2004 | US20040147609 Liquid drug preparations |
| 07/29/2004 | US20040147607 Storage stability |
| 07/29/2004 | US20040147606 Medicinal compositions |
| 07/29/2004 | US20040147594 Compositions and products containing R-equol, and methods for their making |
| 07/29/2004 | US20040147578 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 07/29/2004 | US20040147534 Topical composition and method for treating occlusive wounds |
| 07/29/2004 | US20040147532 Ziprasidone with polymer; sustained release |
| 07/29/2004 | US20040147508 Biologically active methylene blue derivatives |
| 07/29/2004 | US20040147500 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 07/29/2004 | US20040147488 Method of modifying the release profile of sustained release compositions |
| 07/29/2004 | US20040147486 Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders |
| 07/29/2004 | US20040147484 Compositions for delivering bisphosphonates |
| 07/29/2004 | US20040147481 For the manufacture of a medicament for therapy of gastric acid-related diseases and gastro intestinal inflammatory diseases in animals and man, such as gastric ulcer, duodenal ulcer, reflex oesophagitis and gastritis |
| 07/29/2004 | US20040147476 For therapy and prophylaxis of virus infections, other pathogenic infections or cancers |
| 07/29/2004 | US20040147468 Immunostimulatory nucleic acid molecules |
| 07/29/2004 | US20040147437 Calycins |
| 07/29/2004 | US20040147435 Compositions and methods for importing biologically active molecules into cells and for treating inflammation |
| 07/29/2004 | US20040147431 Erythropoietin composition |
| 07/29/2004 | US20040147024 comprising loading a biological sample with a solute by fluid phase endocytosis to produce an internally loaded dehydrated biological sample; for hemostasis aid that can be rehydrated just before the time of application |
| 07/29/2004 | US20040147002 Uses of chemically-modified cholinesterases for detoxification of organophosporus compounds |
| 07/29/2004 | US20040146877 Diagnosis and treatment of cancer:I |
| 07/29/2004 | US20040146563 Mixture of calcium silicate and polyvinylpyrrolidone in aqueous solution; uniform agitation with plant extract drug |
| 07/29/2004 | US20040146562 Depot formulations in the form of a suspension |
| 07/29/2004 | US20040146557 Liquid polymeric compositions for controlled release of bioactive substances |
| 07/29/2004 | US20040146555 Useful in the removal of abnormal keratinous material, as is to be observed, for example, in onychomycoses, psoriasis of the nail, or warts |
| 07/29/2004 | US20040146554 Providing an active pharmaceutical compound; providing a basic salt as one of a powder, a suspension and a solution having a pH greater than 7; combining; delivering the non-enteric coated liquid formulation |
| 07/29/2004 | US20040146550 Block copolymers based on poly(ortho esters) containing amine groups |
| 07/29/2004 | US20040146549 Amino acid sequences capable of facilitating penetration across a biological barrier |
| 07/29/2004 | US20040146538 Pharmaceutical composition for oral use comprising an active principle liable to undergo a large first intestinal passage effect |
| 07/29/2004 | US20040146535 Penetration of active substances through the tissue membrane or barrier of the target organ |
| 07/29/2004 | US20040146534 Vaccine for transcutaneous immunization |
| 07/29/2004 | US20040146532 Agents and methods for treating pain |
| 07/29/2004 | US20040146516 Lumen-exposed molecules and methods for targeted delivery |
| 07/29/2004 | US20040146504 Anti-IgE vaccines |
| 07/29/2004 | US20040146485 Vaccines including as an adjuvant type 1 ifn and process related thereto |
| 07/29/2004 | US20040146477 Cosmetic or pharmaceutical agent |
| 07/29/2004 | US20040146469 Dermal penetration enhancers and drug delivery systems involving same |
| 07/29/2004 | US20040146468 With excipient; suppress or reduce the gustatory function, in particular as regards a bitter and/or sweet and/or acid taste |
| 07/29/2004 | CA2512951A1 Carbohydrate conjugates to prevent abuse of controlled substances |
| 07/29/2004 | CA2512730A1 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 07/29/2004 | CA2512717A1 Compositions and methods for targeted biological delivery of molecular carriers |
| 07/29/2004 | CA2512681A1 Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
| 07/29/2004 | CA2512680A1 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/29/2004 | CA2512676A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
| 07/29/2004 | CA2512672A1 Methods of treating lung diseases |
| 07/29/2004 | CA2512176A1 Anti-protozoal compositions comprising diclazuril |
| 07/29/2004 | CA2509939A1 Thiol-selective water-soluble polymer derivatives |
| 07/29/2004 | CA2506813A1 Peptides which target tumor and endothelial cells, compositions and uses thereof |
| 07/28/2004 | EP1440962A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 07/28/2004 | EP1440698A1 Drug-polymer coated stent with pegylated styrenic block polymers |
| 07/28/2004 | EP1440686A1 Aerosol compositions |
| 07/28/2004 | EP1440682A1 Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 07/28/2004 | EP1440160A1 Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222 |
| 07/28/2004 | EP1440114A1 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 07/28/2004 | EP1439945A1 A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form |
| 07/28/2004 | EP1439860A1 Magnetic nanodispersion comprising cyclodextrines and method for the production thereof |
| 07/28/2004 | EP1439859A1 An antineoplastic- dendritic polymer drug delivery system |
| 07/28/2004 | EP1439858A1 Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| 07/28/2004 | EP1439848A1 L-methionine as a stabilizer for nesp/epo in hsa-free formulations |
| 07/28/2004 | EP1439847A1 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 07/28/2004 | EP1439846A2 Storage-stable human fibrinogen solutions |
| 07/28/2004 | EP1439835A2 Medical compositions for intravesical treatment of bladder cancer |
| 07/28/2004 | EP1439830A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/28/2004 | EP1439829A1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient |
| 07/28/2004 | EP1439828A2 Veterinaire florfenicol formulation that is syringeable under cold weather conditions |
| 07/28/2004 | EP1439826A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 07/28/2004 | EP1439825A1 Methods of treatment using a gastric retained gabapentin dosage |
| 07/28/2004 | EP1439824A2 Three-dimensional suspension printing of dosage forms |
| 07/28/2004 | EP1439823A1 Pharmaceutical formulation comprising (r)-bicalutamide |
| 07/28/2004 | EP1439821A1 Pro-micelle pharmaceutical compositions |
| 07/28/2004 | EP1439820A2 Methods and dosage forms for improving the bioavailability of therapeutic agents |
| 07/28/2004 | EP1439819A1 Formulation of an erodible, gastic retentive oral dosage form using in vitro disintegration test data |
| 07/28/2004 | EP1439818A1 Chewable tablet containing lysine |
| 07/28/2004 | EP1401473A4 Transporters comprising spaced arginine moieties |
| 07/28/2004 | EP1284744B1 Antimigraine combination comprising sapindus and emblica extracts |
| 07/28/2004 | EP1278536B1 Depletion method of blood plasma ascorbate |
| 07/28/2004 | EP1225875B1 Apparatus and process for preparing crystalline particles |
| 07/28/2004 | EP1223990B1 Formulations of hyaluronic acid for delivery of osteogenic proteins |
| 07/28/2004 | EP1220667B1 Beta-agonists for treating endometriosis or infertility, or improving fertility |
| 07/28/2004 | EP1171003B1 Complete feed for fish larvae and method for preparing same |
| 07/28/2004 | EP1077692B1 Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| 07/28/2004 | EP1075461B1 Perfluorinated esters of alkanoyl l-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 07/28/2004 | EP1063968B1 Improved compositions for inhalation |
| 07/28/2004 | EP1061802B1 Topical carbamazepine formulations and methods of use |
| 07/28/2004 | EP0861073B1 Stabilized thyroid hormone preparations and methods of making same |